Eliquis (Apixaban) Patent Expiration, LOE Window & CMS Spending

Eliquis (Apixaban) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2027-05-21 (last listed 2031-08-24), 2 AB generics, $22.07B 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN202155 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2027-05-21
Last Listed Patent or Exclusivity Date2031-08-24
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$22.07B
2024 Medicare Part D Spend$20.77B
2024 Medicaid Spend$1.29B
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.